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Human melanoma ceil lines express many different cytokines [l], including l~photoxin (LT), the production of which has been considered to be 
restricted to cells of the lymphocytic lineage in response to cell activation. LT expression by melanomas is constitutive and characterized by the 
presence of two mRNAs. In the present paper we report an analysis of the origin of the two LT-specific transcripts in four human melanoma cell 
lines at different stages of progression and in four melanocytic ell lines. Reverse transcription-polymerase chain reaction (RT-PCR) performed 
with primers lying in the first and fourth exons and hybridization with intron probes showed a spliced and a full-unspliced LT mRNA. This pattern 
was also displayed by one out of four melanocyte cell lines. Western blot analysis indicated that LT RNA is properly translated to a 23-25 kDa 
protein and immunocytochemistry showed its localization within the cytoplasm and on the cell membrane. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
TNF-a and -/3, the latter also called lymphotoxin 
(LT), are two pleiotropic cytokines which share the 
same receptors and mediate similar functions: they are 
both inflammatory mediators, activate endothelial cells, 
granulocytes and macrophages, stimulate the prolifera- 
tion and differentiation of hemopoietic cells, fibro- 
blasts, T and B lymphocytes, and are cytotoxic for a 
number of tumor cells [2]. Their production has been 
detected in some tumor cell lines and in fresh tumor 
specimens [3-5f. However, while TNF-a has been de- 
scribed in a wide range of histological tumor types 
(ovarian cancer, colon carcinomas, breast and he- 
mopoietic tumors [3-81, LT production is thought to be 
restricted to lymphocytes [9,10], and it has been found 
expressed only in tumors of the lymphoid lineage 
(TALL, Jurkat, Raji) [4], although its expression by 
different type of tumors has not been thoroughly inves- 
tigated. 
We have previously described that human melanoma 
cell lines express a wide range of cytokine, including 
TNF-a and LT. The endogenously produced TNF-cz 
and LT may confer resistance to the cytotoxic effect of 
these cytokines given as recombinant factors [I]. LT 
expression detected by RT-PCR showed two bands in 
melanomas but only one of the two was expressed by 
activated lymphocytes. Here we describe the origin of 
the two LT transcripts in melanomas and provide evi- 
dence of the LT mature protein in these cells. 
*Corresponding author. Fax: (39) (2) 236 2692. 
2.1. Cell culture and RNA extraction 
Melanoma cell lines were isolated from a primary melanoma (4405), 
a subcutaneous metastasis (665/l) and a local relapse of cutaneous 
melanoma (1402/R) from patients at the Istituto Nazionale Tumori; 
WM35 melanoma cell line derives from an early lesion characterized 
by radial growth [ll]. All melanoma cells were cultured in RPM1 1640 
medium supplemented with 5% or 10% FCS at 37°C in a 5% CO* 
atmosphere until1 confluent. Peripheral blood lymphocytes (PBL) 
were purified from healthy volunteer by Ficoll gradient: lo6 cells/ml 
were stimulated in vitro with 1 &ml of PHA for 48 h. Total RNA 
was extracted from cells by guanidinine isothyocyanate and purified 
using a cesium chloride gradient [12]. When indieated, total RNA was 
treated with RQl DNase (Promega Corp., Madison, WI, USA) for 
I5 min at 37°C according to the manufacturer’s conditions and puri- 
fied by pheno~chlorofo~ extraction and ethanol precipitation, prior 
to reverse transcription. RNAs from 4 non-tumorigenic melanocytic 
cell cultures [13] were kindly provided by Dr. M. Herlyn (Winstar 
Institute, Philadelphia, PA, USA) to be analysed together with the 
malignant cells. 
2.2. Reverse transcription polymerase chain reaction Southern blot 
analysis 
One microgram of total RNA was reverse transcribed using 0.5 @g 
of oligo-dT primer (Clontech, Palo Alto, CA, USA) and 600 U of 
MMLV-RT (Gibco BRL, Gaithersburg, MD, USA) at 42°C for one 
hour. One $1 out of 30~1 of cDNA was amplified by 30 cycles of PCR 
with 1 FM of each set of specific primers (Fig. 1). As control of the 
RT efficiency we amplified the 82 mi~oglobulin cDNA with 15-20 
cycles of PCR, to avoid reaching of the plateau of DNA synthesis; in 
this way we could also normalize the amount of cDNA used among 
the sample tested, The PCR product was run on a 2% agarose gel and 
transferred to nylon filters (Hybond Amersham, Buckinghamshire, 
England, UK) by alkaline blotting [12]. The blots were hybridized with 
a full-length LT cDNA probe derived from PHA-stimulated PBL or 
with two synthetic oligonucleotides complementary to sequences in 
the second and third intron of the LT gene. 
Genomic DNA was extracted from melanomas and PHA-stimu- 
lated PBL as described [14]: 5 pg of DNA were digested with AvuI, 
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BarnHI, &OR& PstI and PvuII restriction enzymes (New England 
Biolabs Inc., Beverly, MA, USA) according to the manufacturer’s 
conditions, electrophoresed on 0.8% agarose gel and transferred on 
nylon filters, which were then hybridized with the full length LT 
cDNA probe. After stringent washing the filters were exposed for 
autoradiography using intensifying screens. 
2.3. Western blot analysis and immunocytochemistry 
Melanoma cells and PHA-stimulated PBL were lysed in 10 mM 
Tris-HCl, 0.15 M NaCl, 1% NP40 containing 1 @g/ml aprotinin and 
leupeptidin and 100 pg/rnl phenylmethylsulphonyl fluoride (PMSF). 
The protein content of the cell extracts was measured using the Micro 
BCA Protein Assay Kit (Pierce, Rockford, IL, USA) and equal 
amounts of protein were separated on a 15% SDS-~lyac~lamide gel 
and transferred to nitrocellulose- membranes ~mmobilon-P, Millipore 
Corp., Bedford, MA, USA) by electroblotting [12]. Immunodetection 
of LT was performed by overnight incubation of the filter with 10 
pg/ml of goat-anti human LT (British Bio-technology Ltd., Cowley, 
Oxford, UK) at 4’C. After extensive washing in 10 mM Tris-HCl, 0.15 
M NaCl the filter was incubated with 0.22 @/ml of [‘Z51]protein G 
(Amersham, Buckinghamshire, UK) for 1 h at room temperature, 
repeatedly washed, dried and autoradiographed for 7 days. For im- 
munocytochemical nalysis, 25 x 10’ melanoma cells or PHA-stimu- 
lated PBL were cytocentrifuged on glass slides and tixed in cold 4% 
butTered parafotmaldehyde for 5 min. The slides were incubated over- 
night with diluted rabbit-anti human LT polyclonal antibody (En- 
dogen Inc., Boston, MA, USA) at 4°C; then the slides were sequen- 
tially treated with mouse anti-rabbit and rabbit anti-mouse immunog- 
lobulins, followed by a mouse-APAAP conjugate (Dako A& Glos- 
trup, Denmark); this treatment was repeated twice before addition of 
the chromogenic substrate for the alkaline phosphatase reaction. 
3. RESULTS 
3.1. LT transcription in melanomas and melanocytes 
Nineteen melanoma cell lines were previously 
screened for expression of LT RNA [l]. RT-PCR, per- 
formed with commercial primers (primers 1 and 4, Fig. 
l), showed LT transcription that was characterized by 
two bands in 13 out of 19 lines, while PBL RNA, used 
as a positive control, displayed a single band. Three 
melanoma cell lines (665/l, 1402/R and 4405) were used 
to further investigate the origin of the double band pat- 
tern, that might result from a gene rea~angement or 
represent the expression of an alternatively spliced 
mRNA or simply derive from a DNA contamination of 
the RNA preparation. DNA rearrangement is unlikely 
because Southern blot analysis showed a restriction en- 
zyme pattern that was identical in the DNA of the three 
melanoma cell lines as well as in the DNA from PHA- 
stimulated PBL, digested with five different endonu- 
cleases which do not detect genetic polymorphism (not 
shown). 
RT-PCR performed with a different set of primers 
allowing the amplifi~tion of the entire LT open reading 
frame, thus including the four exons and the three in- 
trons (Fig. lA,B: primers 3 and 2}, confirmed the dou- 
ble band pattern in melanomas but not in activated 
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Fig. 1. RT-PCR analysis of LT expression in human melanomas and schematic representation of the LT gene. Amplification with primers 2 and 
3 reveals the presence of an unspliced mRNA in melanomas but not in PHA-stimulated PBL, detectable both in an ethidium bromide-stained gel 
(A), and after hybridization with a full-length cDNA probe (B); hybridization with an oligonucleotide probe specific for intron 2 shows the 
persistance of unspliced LT mRNA in melanomas (C). DNase treatment of RNA before reverse transcription and amplification with primers 3 
and 4 confirmed that the two LT bands derive from specific transcripts and not from DNA contamination (D). 
115 
Fig. 2. LT expression in four melanocyte cell lines and in the ‘radial 
growth phase’ melanoma WM35, as analysed by RT-PCR performed 
with primers 1 and 2 (Fig. 1) and followed by hybridization with the 
full-length cDNA probe. 
PBL. Band sizes were compatible with a transcript con- 
taining all three introns and with a fully spliced mRNA. 
Hybridization with oligonucleotide probes complemen- 
tary to the second (Fig. 1C) and third intron (not 
shown) confirmed this hypothesis. Finally, DNA con- 
tamination of the starting RNA was excluded by treat- 
ing the total RNA with DNase before reverse transcrip- 
tion and by finding the double band pattern in melano- 
mas but not in PBL RNA after amplification with prim- 
ers 1 and 4 (Fig. 1D). 
In order to see whether spliced and unspliced LT 
RNA are related to either a different degree of tumor 
progression or simply to malignant transformation, 
RT-PCR was performed on additional RNA obtained 
from the WM35 cell line, a radial growth-phase mela- 
noma, and from four foreskin melanocyte cell lines 
(kindly provided by Dr. M. Herlyn). Results showed 
that all samples expressed LT with WM35 and one out 
of four melanocyte lines displayed the doublets (Fig. 2). 
3.2. LT production and cellular localization 
In spite of mRNA expression, LT was undetectable 
by ELISA in the supernatant of Me 665/l, 1402/R and 
4405 [l]. We therefore tested by Western blot and im- 
munocytochemistry whether these melanomas may syn- 
thesize LT. Immunoblotting revealed a specific band of 
23-25 kDa compatible with a monomeric protein of 
molecular size expected from the spliced mRNA (Fig. 
3). 
Immunocytochemistry performed on the same mela- 
noma cell lines showed that LT localizes within the 
cytoplasm and on the cell membrane of the majority of 
the cells (> 95%) (Fig. 4). 
4. DISCUSSION 
Expression of LT in B and T lymphocytes is tightly 
regulated and normally repressed [ 15,161. Its expression 
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is induced by different signals, including antigens, mito- 
gens, phorbol esters and cytokines, such as IL-2 and 
IL-l/? [10,17-201 in both normal lymphocytes and 
tumor cells of lymphoid origin [4,21]. Constitutive ex- 
pression of LT has been rarely reported and confined 
to lymphomas [22], multiple myelomas [23], and to vi- 
rally transformed lymphoid cells, such as B lymphoblas- 
toid cell lines, Raji cells [4,24] and HTLV-I infected 
tumor cell lines [25]. We have previously detected con- 
stitutive expression of LT in most of the melanoma cell 
lines analysed by RT-PCR [l]. Here we demonstrate 
that of the two specific LT transcripts one represents the 
unspliced mRNA, containing all the three introns, and 
that the other is the fully spliced mRNA. 
In the murine T cell line CTLL-2, LT expression is 
induced by IL-2 and is regulated through the alternative 
splicing of an immature polyadenilated mRNA that 
contains all three introns [26] and that gives rise to three 
different mRNAs. A similar mechanism of posttran- 
scriptional regulation could be responsible for the dou- 
ble bands detected by RT-PCR in our melanomas, al- 
though we could not detect any alternatively spliced 
mRNA, but only an immature and fully spliced tran- 
script. As for CTLL-2 cells [26], however, in human 
melanomas the polyadenilation of the LT transcript oc- 
curs before the intron splicing, therefore both mRNAs 
could be reverse transcribed using a poly-dT primer. 
Many other genes appear to be regulated at posttran- 
scriptional evel by either alternative intron splicing, as 
reviewed in [27], or by ordinate removal of all intron 
sequences, as for thymidine kinase or phosphoenolpy- 
ruvate carboxykinase [28,30]; in these cases unspliced, 
spliced and partially spliced mRNAs are detectable. 
Furthermore, the murine lymphoma cell line SL12.4 
shows a posttranscriptional regulation of the TCR-CY 
and -/I chain expression with accumulation of unspliced 
RNA. To detect he spliced form, an appropriate stimu- 
lus should be given: in such a case both unspliced and 
Fig. 3. LT production by human melanomas, analysed by im- 
munoblotting. Equal amounts of protein were loaded per lane and 
separated on 15% SDS-PAGE. Arrow indicates the 23-25 kDa specific 
band detected with anti-human LT antibody. 
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Fig. 4. LT detection by immunocytochemistry. Immunocytochemistry 
was performed using the APAAP technique on melanoma cells and 
showed LT-positive staining in the cytoplasm and on the cell mem- 
brane. 665/l (right) and 140UR (left) cell lines are shown as represen- 
tative of the melanomas analysed. 
spliced mRNAs become detectable within these cells 
[30,31]. This pattern of gene expression in SL12.4 lym- 
phoma is most similar to that occurring for LT in the 
melanomas analysed in this study, since both show the 
persistance of the unspliced and the fully spliced RNAs. 
What is different between these two tumors is that 
SL12.4 cells display the spliced RNA only after appro- 
priate treatment, while in melanomas the two RNAs 
seem constitutive. Without success we tried to modulate 
LT expression by treatment with TNF-a and IFN-)I 
given, alone or in combination, at doses known to mod- 
ulate the expression of various molecules, such as inte- 
grins, tumor-ass~iated antigens and HLA class II anti- 
gen on melanomas [32]. 
Normal PBL stimulated with PHA expressed only the 
mature form of LT mRNA, suggesting that in melano- 
mas its expression might be related to the malignant 
phenotype and that the anomalous two-band pattern 
may be linked to tumor progression. Southern blot 
analysis rejected the hypothesis of a rearrangement in 
the LT gene and RT-PCR revealed that LT was indeed 
expressed in four melanocyte cultures, one of which 
displayed the unspliced mRNA also. This different 
RNA pattern might represent a peculiar posttranscrip- 
tional regulation occurring in cells of the melan~yti~ 
lineage or might indicate an impai~ent of the RNA 
splicing machinery in the melanoma cells. The analysis 
of four melanocytic cell lines may be insufficient to 
conclude that the double band pattern is restricted to 
the transformed phenotype; the finding in one out of 
four melanocyte cultures of the unspliced LT mRNA 
band does not rule out this hypothesis. It should be 
considered that melanocytes are kept in culture with 
promoting agents like TPA [33] and, although other 
phenotypic markers are compatible with a non-trans- 
formed state, these growth conditions might interfere 
with some biological function. 
Although the secreted form of LT was undetectable 
by ELISA assay [I], LT detection was possible by West- 
em blot and immunocytochemistry, thus suggesting 
that its localization was confined to the cytoplasm and 
the cell membrane. 
The presence of a single LT specific band of 23-25 
kDa in Western blots indicates that the immature RNA 
could not be translated to give a new protein, as was 
suggested by Weil for the murine LT mRNAs obtained 
from the CTLL-2 cell line f26J. However we could not 
exclude the possibility that a putative alternative pro- 
tein might exist but lacking the epitopes recognized by 
our antibody. While the relative amount of the two LT 
mRNA forms is different among the melanoma cell 
lines (Fig. l), the presence of a LT monomeric protein 
of the correct size, particularly in the 1402/R cell line 
that mostly expresses the unspliced mRNA form, sug- 
gests that splicing occurs in all the cell lines thus giving 
rise to a functional mRNA. 
The functional role of LT expression by melanoma 
cells remains unknown. Easier speculation might be 
possible if a soluble protein could have been detected, 
thus allowing to consider all the LT paracrine effects, 
for example its osteolytic and bone resorption activity 
that might facilitate tumor spreading to bones [23,24]. 
In addition, LT has been described to be cytotoxic for 
the same cells producing it, as for stimulated B and T 
lymphocytes [35]. This observation suggested a role for 
LT in immunoregulation and ontogeny of B and T lym- 
phocytes [9,18,36] but may also suggest apossible mech- 
anism of tumor-derived immune-suppression. Finally, 
LT production even if confined to the membrane and 
cytoplasm of tumor cells, might represent a mechanism 
of escape from the cytotoxic effects of T cell-produced 
LT and of mono~yte-produced TNF-a 136,371. 
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